GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sysmex Corp (TSE:6869) » Definitions » Net-Net Working Capital

Sysmex (TSE:6869) Net-Net Working Capital : 円64.34 (As of Dec. 2023)


View and export this data going back to 1996. Start your Free Trial

What is Sysmex Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Sysmex's Net-Net Working Capital for the quarter that ended in Dec. 2023 was 円64.34.

The industry rank for Sysmex's Net-Net Working Capital or its related term are showing as below:

TSE:6869's Price-to-Net-Net-Working-Capital is ranked worse than
91.43% of 455 companies
in the Medical Devices & Instruments industry
Industry Median: 6.58 vs TSE:6869: 41.35

Sysmex Net-Net Working Capital Historical Data

The historical data trend for Sysmex's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sysmex Net-Net Working Capital Chart

Sysmex Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Net-Net Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 95.32 53.95 74.91 95.34 92.91

Sysmex Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 84.89 92.91 96.01 109.79 64.34

Competitive Comparison of Sysmex's Net-Net Working Capital

For the Medical Instruments & Supplies subindustry, Sysmex's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sysmex's Price-to-Net-Net-Working-Capital Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sysmex's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Sysmex's Price-to-Net-Net-Working-Capital falls into.



Sysmex Net-Net Working Capital Calculation

Sysmex's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Mar. 2023 is calculated as

Net-Net Working Capital(A: Mar. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(70335+0.75 * 126319+0.5 * 73310-142718
-0-690)/627.741
=92.91

Sysmex's Net-Net Working Capital (NNWC) per share for the quarter that ended in Dec. 2023 is calculated as

Net-Net Working Capital(Q: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(60694+0.75 * 132749+0.5 * 81724-160273
-0-738)/623.388
=64.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


Sysmex  (TSE:6869) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


Sysmex Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Sysmex's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Sysmex (TSE:6869) Business Description

Traded in Other Exchanges
Address
1-5-1 Wakinohara-Kaigandori, Chuo-ku, Hyogo Prefecture, Kobe, JPN, 6510073
Sysmex Corp manufactures and distributes in vitro diagnostic instruments, reagents, and software. The vast majority of the firm's revenue comes from selling tests for human bodily fluids to hospitals and commercial laboratories. Within this industry, the firm specializes in hematology reagents and instruments. Sysmex also sells in vitro diagnostics for applications like urinalysis and hemostasis and provides support and maintenance services for its systems. Over half of the firm's revenue is generated by sales of reagents and services, which are recurring sources of income. Sysmex primarily sells its products to customers in Japan, Europe, the Middle East, and Africa, and the Americas.

Sysmex (TSE:6869) Headlines

No Headlines